News
Capricor's DMD therapy Deramiocel is under FDA Priority Review with no major issues flagged; PDUFA date set for August 31, 2025.
3h
Stocktwits on MSNCapricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues WarningCapricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee ...
From 1990 to 2021, the global burden of musculoskeletal disorders (MSDs) among postmenopausal women (PMW) grew significantly, and 2045 projections indicate this trend will continue, according to a ...
The results indicated that subjects who switched from alglucosidase alfa to cipa+mig generally achieved improvements or ...
Island Health has placed three beaches on advisories, two for high enterococci levels and a third for blue-green algae.
For the first time in the world, a Korean research team discovered how cellular aging can spread systemically through the ...
Homedics, a global leader in personal wellness technology, recently launched the Glo Body Analyser Bathroom Scale and the Glo ...
"The most common sign of a vitamin D deficiency would be aches in the muscles and bones," points out Dr Claire Gorman, ...
Zebrafish have the remarkable and rare ability to regrow and repair their hearts after damage. New research from Caltech and ...
Sarepta has issued a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl) following a second reported case of acute liver failure resulting in death.
FDA has indicated that an Advisory Committee meeting is not required at this timeIn-person late-cycle review meeting ...
The U.S. Food and Drug Administration is due to review data on deramiocel, a cell therapy up for approval for heart disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results